Dr. Nusayba Bagegni, M.D.
Claim this profileWashington University School of Medicine
Expert in Breast Cancer
Studies Breast cancer
19 reported clinical trials
61 drugs studied
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Breast Cancer
HER2 positive
ER negative
Stage IV
Affiliated Hospitals
Clinical Trials Nusayba Bagegni, M.D. is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Biomarker-Guided Neoadjuvant Therapy
for Breast Cancer
This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.
Recruiting1 award Phase 212 criteria
More about Nusayba Bagegni, M.D.
Clinical Trial Related1 year of experience running clinical trials · Led 19 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Nusayba Bagegni, M.D. has experience with
- Paclitaxel
- DiviTum® TKa Assay
- Fulvestrant
- Tucatinib
- Trastuzumab
- Pertuzumab
Breakdown of trials Nusayba Bagegni, M.D. has run
Breast Cancer
Breast cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nusayba Bagegni, M.D. specialize in?
Nusayba Bagegni, M.D. focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Nusayba Bagegni, M.D. currently recruiting for clinical trials?
Yes, Nusayba Bagegni, M.D. is currently recruiting for 14 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Nusayba Bagegni, M.D. has studied deeply?
Yes, Nusayba Bagegni, M.D. has studied treatments such as Paclitaxel, DiviTum® TKa assay, Fulvestrant.
What is the best way to schedule an appointment with Nusayba Bagegni, M.D.?
Apply for one of the trials that Nusayba Bagegni, M.D. is conducting.
What is the office address of Nusayba Bagegni, M.D.?
The office of Nusayba Bagegni, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.